Metastatic Pancreatic Cancer
Novocure GmbH supports clinical research in metastatic pancreatic ductal adenocarcinoma, with a focus on treatment settings for patients receiving first-line systemic therapy. The studies centre on tumor treating fields in combination with established chemotherapy and immunotherapy approaches.
- Metastatic pancreatic ductal adenocarcinoma
- Tumor treating fields
- Gemcitabine
- Nab-paclitaxel
- Atezolizumab
The therapeutic interest in this area reflects work at the intersection of solid tumor management, systemic anticancer therapy, and device-based oncology.
Glioblastoma
Research activity also includes newly diagnosed glioblastoma, where the sponsor examines Optune alongside standard temozolomide treatment and pembrolizumab. This area is directed toward patients with aggressive primary brain tumors.
- Newly diagnosed glioblastoma
- Optune
- Temozolomide
- Pembrolizumab
- Primary brain tumors
The clinical focus combines neuro-oncology with device-based treatment strategies and immunotherapy-based combinations.
Oncology Combination Therapy
The sponsor’s clinical portfolio spans combination treatment approaches in oncology, including integration of tumor treating fields with immune checkpoint inhibitors and cytotoxic agents. These studies address treatment-resistant and advanced solid tumors.
- Immune checkpoint inhibitors
- Solid tumors
- Combination therapy
- Systemic anticancer therapy
This work links device-mediated cancer treatment with established pharmacologic regimens in difficult-to-treat malignancies.
Neuro-Oncology and Solid Tumor Care
Novocure’s funded research is concentrated in neuro-oncology and advanced solid tumor care, with active interest in both intracranial and extracranial malignancies. The disease areas studied include cancers with high unmet clinical need.
- Neuro-oncology
- Brain cancer
- Advanced solid tumors
- High unmet need malignancies
Its research landscape is shaped by therapeutic development at the interface of oncology, medical devices, and combination regimens.
